CNTA 주가 차트
CNTA 수입
Centessa Pharmaceuticals PLC
$40.5
0%
$0
종가: Jun 25, 16:00:00 GMT-4
$40.5
0%
$0
애프터마켓: Jun 25, 20:13:26 GMT-4
뒤로
Centessa Pharmaceuticals PLC (CNTA) 수입
최신 수익 결과: Q1 '26
보고됨: 2026-05-05
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
CNTA의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Centessa Pharmaceuticals PLC CNTA의 지난 분기 매출 실적은 어땠나요?
Centessa Pharmaceuticals PLC의 매출 추정치는 얼마인가요?
Centessa Pharmaceuticals PLC의 수익 품질 점수는 얼마인가요?
Centessa Pharmaceuticals PLC는 언제 수익을 보고하나요?
Centessa Pharmaceuticals PLC의 예상 수익은 얼마인가요?
Centessa Pharmaceuticals PLC은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$40.5
시가
$40.14
일일 범위
$40 - $40.56
52주 범위
$10.95 - $40.5
거래량
11.2M
평균 거래량
2.1M
배당수익률
--
EPS(TTM)
-1.77
시가총액
$6.2B
CNTA란 무엇인가요?
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 118 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
